126
Views
6
CrossRef citations to date
0
Altmetric
Research Articles

Short-term comparative study of the effects of preserved and unpreserved topical levofloxacin on the human ocular surface

, &
Pages 247-253 | Received 21 Mar 2010, Accepted 08 May 2010, Published online: 16 Jun 2010

References

  • Chisari G, Cavallaro G, Reibaldi M, Biondi S. Presurgical antimicrobial prophylaxis: effect on ocular flora in healthy patients. Int J Clin Pharmacol Ther 2004; 42:35–38.
  • Scoper SV. Review of third- and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Adv Ther 2008; 25:979–994.
  • Manni G, Centofanti M, Oddone F, Parravano M, Bucci MG. Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol 2005;139:72–77.
  • Baffa Ldo P, Ricardo JR, Dias AC, Módulo CM, Braz AM, Paula JS, et al. Tear film and ocular surface alterations in chronic users of antiglaucoma medications. Arq Bras Oftalmol 2008; 71:18–21.
  • Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol 2009; 3:291–295. Epub 2 Jun 2009.
  • Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008; 17:350–355.
  • Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341–349.
  • Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm 2002; 53:263–280.
  • Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003; 12:486–490.
  • Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86:418–423.
  • Nelson JD. Impression cytology. Cornea 1988; 7:71–81.
  • Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18:205–215.
  • Ayaki M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. Clin Exp Ophthalmol 2008; 36:553–559.
  • Kovoor TA, Kim AS, McCulley JP, Cavanagh HD, Jester JV, Bugde AC, et al. Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens 2004; 30:90–94.
  • Dutot M, Pouzaud F, Larosche I, Brignole-Baudouin F, Warnet JM, Rat P. Fluoroquinolone eye drop-induced cytotoxicity: role of preservative in P2X7 cell death receptor activation and apoptosis. Invest Ophthalmol Vis Sci 2006; 47:2812–2819.
  • Debbasch C, Brignole F, Pisella PJ, Warnet JM, Rat P, Baudouin C. Quaternary ammoniums and other preservatives’ contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001; 42:642–652.
  • Tiffany JM. The normal tear film. Dev Ophthalmol 2008; 41:1–20.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.